Prof Sherene Loi speaks to ecancer about the landscape and clinical relevance of genomic alterations in premenopausal HR+, HER2-negative early breast cancer.

She outlines the latest research from the SOFT study which aims to better understand the biology of breast cancer diagnosed in premenopausal women versus post-menopausal women.

Prof Loi concludes her presentation by looking towards the future, suggesting we need to develop more specific trials to focus on very young women in order to improve breast cancer outcomes.